Contrarian Corpus
activist full deck proxy fight
2015-02-17 · 95 pages

E.I. du Pont de Nemours and Company (DuPont) DD

DuPont is an underperforming conglomerate burdened with $2-4bn of excess costs; elect Trian's four nominees to drive separation, cost cuts, and board accountability.

N 5 Narrative
V 3 Visual
C 3 Craft
Original source ↗

Thesis

Trian, with ~$1.9bn invested making it one of DuPont's largest shareholders, seeks four minority board seats after two years of rejected settlement offers and three consecutive years of missed guidance. The deck argues DuPont's 'state of perpetual transformation' — 16 years of divestitures with no stock price progress, bottom-quartile EPS growth versus every peer set, and margins trailing peers in five of seven segments — stems from an overly complex conglomerate burdened with an estimated $2-4bn of excess corporate costs, vividly evidenced by Coatings EBITDA growing 150% after leaving DuPont's umbrella as Axalta. Trian's four nominees (Peltz, Myers, Winkleblack, Zatta) will assess whether best-in-class performance is achievable in the current structure or requires separation, eliminate excess costs, re-examine capital allocation, and install the ownership mentality missing from a Board whose independent directors collectively own just $20m of stock.

SCQA

Situation

DuPont is a ~$35bn revenue diversified chemicals and industrials conglomerate with seven segments under CEO Ellen Kullman, positioned by management as a transforming higher-growth, higher-value science company.

Complication

DuPont has missed guidance three straight years, delivered bottom-quartile EPS growth versus every peer set, and carries an estimated $2-4bn in excess corporate costs — Trian argues conglomerate complexity is the root cause.

Resolution

Elect Trian's four minority nominees (Peltz, Myers, Winkleblack, Zatta) to assess potential separation, eliminate excess corporate costs, re-examine capital allocation, and restore accountability — after settlement offers since 2013 were rejected.

Reward

Precedent spin-offs (PPG re-rated 33%, Ingersoll-Rand/Allegion multiple +113%, Axalta EBITDA +150%) show the upside; Trian argues DuPont's ~53% share rise since their investment already prices in their involvement.

The three reasons

  1. 1

    DuPont has missed guidance three straight years and posted bottom-quartile EPS growth versus every relevant peer group

  2. 2

    Conglomerate complexity hides $2-4bn of excess corporate costs — Coatings EBITDA grew 150% after DuPont sold it as Axalta

  3. 3

    Independent directors own only ~$20m of stock and have failed to hold management accountable; Trian's four nominees bring ownership mentality

Primary demands

  • Elect Trian's four nominees (Nelson Peltz, John H. Myers, Arthur B. Winkleblack, Robert J. Zatta) as a minority slate on the DuPont Board
  • Assess corporate structure and determine whether separation of the portfolio is required to achieve best-in-class revenue growth and margins
  • Eliminate excess corporate costs (Trian estimates $2-4bn annually) and implement zero-based budgeting
  • Re-evaluate capital allocation including R&D, M&A discipline, balance sheet leverage, and capital return policies (including increasing dividends)
  • Enhance corporate governance: increase transparency, fix the entrenched Chemours spin-off governance, and align compensation with actual performance

KPIs cited

EPS growth 2011-2013 vs peers
DuPont -10%, bottom-quartile vs both proxy peers (range -15% to +51%) and diversified industrials/chemicals peers (range -15% to +32%)
Excess corporate costs
Trian estimates $2-4bn annually; ~$907m of publicly disclosed unallocated corporate costs
Coatings / Axalta EBITDA
$339m under DuPont (2011A) vs $852m LTM 9/30/14 under PE (+150%); S-1 disclosed $229m of excess corporate costs burdened on the segment
Total Shareholder Return (20-year)
DuPont 327% — lowest among diversified industrials/chemicals peer set (DHR 2,671%, BASF 1,944%, UTX 1,882%)
Danisco organic growth
3.1% actual vs 8-10% 2011 long-term target; Nutrition & Industrial Biosciences EBIT margins down 33% since 2010PF
Agriculture R&D productivity
~$5bn R&D over 5 years produced no significant new biotech traits; $1bn Monsanto patent verdict; $1.2bn Imprelis charges on ~$7m of sales
Short-term incentive payouts vs performance
STI payouts 86-87% in 2012-2013 despite revenue and EPS growth far below long-term targets
CEO insider selling
Kullman sold 23% of her equity position ($49m+) after Trian white paper released, at 15-year share price high

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • Heinz (Trian 2006 proxy contest, 178% TSR through 2013 sale)
  • Ingersoll-Rand / Allegion spin-off (2012-2014)
  • PPG Industries commodity chemicals spin-off (2012-2013)
  • Axalta (ex-DuPont Coatings under PE — EBITDA +150%)
  • Rockwood Holdings (Bob Zatta case study)
  • Triangle Industries / American National Can (Peltz case study)
  • Snapple turnaround (Triarc, Harvard Business School case)

Notable slides (6)

Notes

Classic proxy-fight deck with strong SCQA structure. Distinctive rhetorical moves: (1) 'Did DuPont Learn Anything From Heinz?' slide (p11/37) uses a three-column table to preempt management's standard anti-activist playbook by showing their 2014 claims almost verbatim match Heinz's 2006 claims that were later proven wrong. (2) Coatings/Axalta case study (p13/70) is a devastating natural experiment — same segment, same year, different owners, +68% EBITDA. (3) Peer-gap charts presented across multiple timeframes (latest cycle, 10-year, 20-year) on pp. 43-44 to preempt cycle-selection objections. Deck is explicit that Trian is 'open-minded' about separation vs. fixing current structure — hedged demand. Stake disclosed as ~$1.9bn dollar value, not as a percentage. Consistent 'DuPont Can Be Great' yellow watermark throughout. Trian ultimately lost the May 2015 proxy vote narrowly, but the thesis was largely vindicated by the subsequent Dow-DuPont merger/breakup.